Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • NEWS

Pioneering antisense drug heads into pivotal trials for Huntington disease

Gene-silencing therapies promise progress in neurodegenerative diseases, with Roche and Ionis Pharmaceuticals testing whether such a drug can delay the progression of Huntington disease.
  1. Asher Mullard
    View author publications

    You can also search for this author in PubMed  Google Scholar

Credit: Ralwel/iStock/Getty Images Plus

A phase III trial of Roche and Ionis’s RG6042 is recruiting patients with Huntington disease (HD) to test whether a gene-silencing drug can slow the progression of a neurodegenerative disease. A positive outcome would be a much-needed boon for patients, while boosting enthusiasm for related strategies in other neurodegenerative diseases in which the accumulation of aberrant proteins damages the brain.

Access options

Rent or buy this article

Prices vary by article type

from$1.95

to$39.95

Learn more

Prices may be subject to local taxes which are calculated during checkout

Nature Reviews Drug Discovery 18, 161-163 (2019)

doi: https://doi.org/10.1038/d41573-019-00018-7

Subjects

Latest on:

Nature Careers

Jobs

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing

Search

Advanced search

Quick links